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When a diagnosis of invasive candidiasis has been made, treatment with toxic fungicidal agents is inevitable.
The crucial decision of when to stop such treatment is difficult to make, because cultures are often negative
despite ongoing invasive candidiasis and can therefore not be used as a reliable parameter of effective therapy.
In the present study, the use of PCR in monitoring the therapeutic efficacy of antifungal treatment with
liposomal amphotericin B was evaluated by using neutropenic mice with systemic candidiasis. Blood cultures
of infected mice treated with different doses of liposomal amphotericin B were only positive at the early onset
of the infection process and became sterile within 3 days; this was true even with mice treated with 1 mg of
liposomal amphotericin B per kg of body weight that experienced a relapse of infection 14 days later. A
significant correlation between presence of Candida albicans in the kidneys and PCR results obtained with
blood was demonstrated. Thus, PCR results obtained with blood samples correlated well with the therapeutic
efficacy of antifungal treatment.
Invasive candidiasis is an important cause of mortality and
morbidity, particularly in immunocompromised patients. Un-
fortunately, efficient diagnosis is hampered by the lack of clin-
ical parameters that can be used to recognize invasive candi-
diasis. A combination of microbiological, histological, and
serological results may sometimes contribute to the diagnosis,
but these tests are not 100% sensitive and specific (3). Re-
cently, non-culture-dependent assays such as the PCR have
gained increasing importance in the rapid diagnosis of infec-
tions in patients at risk (10). The contribution of PCR assays in
the diagnosis of fungal infections has now been demonstrated
with a wide variety of clinical specimens, including blood, se-
rum, respiratory secretions, urine, peritoneal fluid, and cere-
brospinal fluid (2, 4–7, 9, 12). It has been demonstrated that
PCR has a better sensitivity than blood cultures in detecting
Candida albicans infection in persistently neutropenic mice
(14). Apart from helping to diagnose invasive candidiasis, an
ideal assay should also help in monitoring the response to
treatment and thus in determining the duration of therapy.
Since toxic fungicidal agents are used, achieving accurate esti-
mates of the time at which treatment can be stopped is clini-
cally highly relevant. In the present study, we evaluated the use
of PCR in monitoring the response to antifungal treatment
with a liposomal formulation of amphotericin B (AmB) (Am-
Bisome) in neutropenic mice with systemic candidiasis. PCR
results were compared with blood culture results at several
time points during the course of the infection.
(Part of this research was presented at the 35th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, Calif., 17 to 20 September 1995.)
MATERIALS AND METHODS
Animals and C. albicans strain. Specific-pathogen-free, 11- to 13-week-old
female BALB/c mice weighing 22 6 1.3 g were used (Iffa Credo, L’Arbresle,
France). C. albicans (ATCC 44858) was used throughout all the experiments.
The yeast was stored at 2808C in Todd-Hewitt broth (Difco Laboratories,
Detroit, Mich.) containing 10% (vol/vol) glycerol. Stationary-growth-phase cul-
tures were obtained after incubation of C. albicans in Sabouraud maltose broth
(Difco Laboratories) for 24 h at 378C. Yeast cells were washed in phosphate-
buffered saline (PBS), counted in a hemocytometer, and adjusted to 53 104 cells
per ml in PBS.
Antifungal agent. AmB, encapsulated in small unilamellar vesicles consisting
of hydrogenated soybean phosphatidylcholine, cholesterol, and distearoylphos-
phatidylglycerol in a molar ratio of 2:1:0.8, was kindly provided by Vestar Inc.
(San Pimas, Calif.) as a lyophilized preparation. The powder was reconstituted
with distilled water at 658C according to the manufacturer’s instructions to give
a liposomal suspension containing 4 g of AmB per liter and 35 g of lipid per liter.
Systemic infection in neutropenic mice. A model of invasive candidiasis in
persistently neutropenic mice, as previously described, was used (15). Briefly,
neutropenia was induced by intraperitoneal administration of cyclophosphamide
(Sigma Chemical Co., St. Louis, Mo.) at 100 mg/kg of body weight 4 days prior
to inoculation with C. albicans, followed by additional doses of 75 mg/kg on the
day of inoculation and at 3-day intervals during the course of infection (15). This
treatment resulted in persistent granulocytopenia of,100 granulocytes per ml of
blood from the time of inoculation with C. albicans up to termination of the
studies.
In each experiment, 19 neutropenic mice were infected by inoculation of 200
ml of 5 3 104 C. albicans CFU/ml in the tail vein. AmB was administered
intravenously (i.v.) for 4 consecutive days at a dose of 1, 7, or 14 mg/kg of body
weight. At 1 h or 3, 6, 14, 21, and 35 days after inoculation with C. albicans,
groups of three to four mice were sacrificed and blood was collected in EDTA-
coated tubes by cardiac puncture. Of each blood sample, 100 ml was directly
cultured on Sabouraud dextrose agar (SDA) plates (Oxoid, Basingstoke, En-
gland) and incubated for 5 days at 378C. Another 100 ml of blood was used for
DNA extraction.
The kidneys, spleen, liver, and lungs were removed from each mouse and
separately homogenized in 20 ml of PBS for 30 s at 10,000 rpm in a VirTis
homogenizer (VirTis Co. Inc., Gardiner, N.Y.). Residual AmB was eliminated
from the homogenates by washing the sediment after centrifugation three times
with PBS. Two hundred microliters of the serial 10-fold dilutions of each homo-
genate was plated on SDA plates. Two milliliters of the homogenate and the
remainder of the homogenate, together with 18 ml and an equal volume of
double-strength SDA, respectively, were mixed and poured into petri dishes. All
plates were incubated for 48 h at 378C.
PCR sample preparation. For Candida DNA extraction from blood we used a
method modified from that of Buchman et al. (2, 14). Briefly, 0.1 ml of lysis buffer
(0.32 M sucrose, 10 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 1% Triton X-100) was
added to 0.1 ml of whole blood. After lysis, cell debris and Candida cells were
pelleted by centrifugation (Eppendorf centrifuge; Merck, Amsterdam, The Neth-
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erlands) at 16,000 3 g for 5 min. The pellet was resuspended in 0.2 ml of lysis
buffer. To remove free, non-yeast-cell DNA, 7 ml of DNase (10 mg/ml; Boehr-
inger Mannheim Gmbh, Mannheim, Germany) was added and the samples were
incubated at 378C for 1 h. After centrifugation at 16,000 3 g for 5 min, pellets
were resuspended in 0.2 ml of TEG buffer (50 mM glucose, 25 mM Tris-HCl [pH
8.0], 10 mM EDTA) containing 1.5 ml of Lyticase (900 U/ml; Sigma Chemical
Co.) and incubated for a further 1 h at 378C. Subsequently, 3.0 ml of pronase (15
mg/ml; Boehringer Mannheim) and 10 ml of 10% sodium dodecyl sulfate (SDS)
were added and incubation was continued for 1 h at 378C. DNA extraction and
purification were realized by using Prep-A-Gene DNA Matrix according to the
instructions of the manufacturer (Bio-Rad Laboratories, Richmond, Calif.). The
matrix was eluted with 40 ml of TE buffer (10 mM Tris-HCl [pH 8.0] and 1 mM
EDTA).
Filter tips (Biozym, Landgraaf, The Netherlands) were used throughout the
whole isolation procedure to avoid contamination.
Primers and PCR protocol. PCR was performed in a 100-ml volume under
standard conditions with 5 and 10 ml of the DNA samples. The following primer
set, generating a 180-bp fragment spanning the V4 region of the small subunit-
rRNA gene, was used: 532 (59-TATTAAAGTTGTTGCAG-39) and 651 (59-
CCTGCTTTGAACACTCTAATTT-39) (10). PCR was performed in 100 ml of
PCR solution, containing 50 mMKCl, 10 mM Tris-HCl (pH 8.3), 2.5 mMMgCl2,
200 mM each deoxynucleoside triphosphate, 50 pmol of each primer, 0.1 mg of
gelatin per ml, 1 U of Taq DNA polymerase (Promega, Leiden, The Nether-
lands), and 5 or 10 ml of sample. The reaction mixture was overlaid with 100 ml
of mineral oil (Sigma) to prevent evaporation and was preincubated for 5 min at
948C for DNA denaturation. Forty cycles of amplification were performed with
a PCR processor (Biomed Gmbh, Theres, Germany). Each cycle consisted of a
denaturation step at 948C for 1 min, a primer-annealing step at 528C for 1.5 min,
and a chain elongation step at 748C for 1 min. After 40 cycles, a temperature
delay step of 5 min at 748C completed elongation. A 30-ml volume of the
amplified PCR product was analyzed by agarose (1.5%, wt/vol) gel electrophore-
sis.
Southern blot analysis of PCR products. DNA was transferred from agarose
to Hybond Plus nylon filters (Amersham International, plc, Amersham, United
Kingdom) by overnight diffusion blotting in 0.4 N NaOH. The PCR products
were analyzed with the C. albicans-specific probe (59-GTAGCCATTTATGGC
GAACC-39) (10). Membranes were preincubated at 378C in a hybridization
solution (53 SSC [13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 13
Denhardt’s solution) for 1 h. Hybridization occurred overnight at 378C with 20
pmol of T4 polynucleotide kinase (Bethesda Research Laboratories, Inc.) and
[g-32P]ATP (3,000 Ci/mmol; Amersham International, plc)-labelled oligonucle-
otide probe. The filters were washed once for 15 min at 378C and once for 15 min
at 558C with 23 SSC–0.1% (wt/vol) SDS. Autoradiography was performed with
Kodak Royal X-Omat film and a 3.5-h exposure time.
RESULTS
Optimization of Candida PCR. To rule out an inhibitory
effect of residual AmB on the PCR assay, blood of mice pre-
treated with AmB at 17 mg/kg for 4 days was spiked with a
10-fold dilution series of 2,000 to 2 cells of C. albicans and
incubated for 30 min at 378C and then tested in the PCR assay.
No difference in the lower limit of detection was found be-
tween blood of treated and untreated mice (data not shown).
In a previous study, we used 10 ml of DNA sample in the final
PCR (10). In the present study, we tried to improve the sen-
sitivity of the PCR assay by adding several volumes of extracted
DNA obtained from blood samples spiked with different num-
bers of yeast cells. No significant differences were obtained by
using either 5 or 10 ml of extracted DNA sample in this in vitro
experiment. However, the sensitivity of the PCR decreased
100-fold if 15 ml of the same DNA sample was used (Fig. 1).
We thus decided to use 5 ml as well as 10 ml of DNA samples
in the current study.
PCR monitoring of invasive candidiasis. After challenge
with C. albicans, AmB was administered for 4 consecutive days
at a dose of 1, 7, or 14 mg/kg of body weight. In mice treated
with 1 mg of AmB per kg, an initial drop in CFU per organ in
lungs, livers, and spleens was observed and then there was an
increasing number of CFU per organ from 14 to 21 days after
inoculation (Fig. 2). The number of CFU in the kidneys, how-
ever, remained stable and increased from 104 at day 14 to 106
at day 35.
Cultures from lungs, livers, and spleens of mice treated with
7 and 14 mg of AmB per kg became sterile within 3 days of
FIG. 1. Southern blot analysis of C. albicans PCR products obtained by
amplification of different volumes of processed blood samples spiked with 2,000,
200, 20, 10, 2, and 0 (negative control [2]) C. albicans cells per 100 ml of blood.
Lanes 1 to 5 represent the dilution series obtained by amplification of 5, 10, and
15 ml of processed blood (lane sets from left to right); 1, positive control (whole
blood spiked with C. albicans cells).
FIG. 2. Progression of systemic infection in neutropenic mice treated with 4
daily doses of 1 mg of AmB per kg (A), 7 mg of AmB per kg (B), 14 mg of AmB
per kg of body weight (C). Data are expressed as the mean number 6 standard
error (error bars) of CFU of C. albicans in kidneys (h), spleens (E), lungs (),
and livers (}). Data are based on three to four mice each group.
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treatment (Fig. 2). In contrast, the number of CFU in the
kidneys of mice treated with 7 and 14 mg of AmB per kg
decreased only slowly and cultures became sterile between
days 14 and 21 (Fig. 2). Eight of nine blood samples taken 1 h
after the challenge grew C. albicans (Table 1). Of the mice
treated with 1 mg of AmB per kg, only one had a C. albicans-
positive blood culture for the sample taken 3 days after the
challenge. All other blood samples taken later in the infection
process in all three treatment regimens failed to grow C. albi-
cans.
The PCR results obtained by amplification of 5 ml of target
DNA (Fig. 3) of blood samples of mice treated with 1 mg of
AmB per kg show an initial decrease in PCR hybridization
signals, which were absent on day 14. However, at day 21 PCR
gave positive results again (Table 1). PCR with 10 ml of target
DNA (Fig. 4) actually demonstrated that a constant level of
target DNA was present in the blood; however, the intensity of
the hybridization signals of samples taken on day 35 was
higher.
Mice treated with 7 mg of AmB per kg showed positive PCR
results only at 1 h and 35 days if 5 ml of target DNA was used.
PCR with 10 ml showed a similar profile. However, more often
a positive PCR result was found between 1 h and 35 days (Fig.
3 and 4; Table 1). Samples from mice treated with 14 mg of
AmB per kg gave several positive PCR signals over time if 5 ml
was used; however, 5-ml target DNA samples were all PCR
negative at day 35. If 10 ml was used, only negative PCR signals
were obtained (data not shown).
A positive correlation between the PCR results obtained by
using 10 ml of processed sample for all three treatment regi-
mens and the positive kidney cultures of the mice was demon-
strated (P 5 0.04; Fisher extract test). No such correlation
could be demonstrated with the data from PCR with 5 ml of
processed blood sample.
DISCUSSION
Generally, it takes 2 to 7 days for Candida spp. to grow from
patients’ specimens. Therefore, microbiological culture cannot
be regarded as an early diagnostic tool. Furthermore, even the
best blood culture technique often gives negative results de-
spite evidence of systemic infection (1). A breakthrough in
diagnostic microbiology has been the introduction of the PCR
technique for the detection of Candida spp. in several clinical
specimens (8, 11). In a previous study, we demonstrated that
PCR was more sensitive than culture in detecting C. albicans in
blood from neutropenic mice with invasive candidiasis (14).
Once the diagnosis of invasive candidiasis has been made,
treatment with toxic fungicidal agents is inevitable. The deci-
sion of when to stop treatment is even more difficult to make,
since negative cultures are not always indicative of a therapeu-
tic response. Therefore, the aim of the present study was to
examine the usefulness of PCR as an assay to monitor the
response to AmB in neutropenic mice with invasive candidia-
sis.
FIG. 3. Southern blot analysis of 5 ml of C. albicans PCR products obtained
from blood samples from mice treated with 1 (top), 7 (middle), and 14 (bottom)
mg of AmB per kg. Lanes 1 to 3, 4 to 6, 7 to 9, 10 to 12, 13 to 16, and 17 to 19
represent mice sacrificed at 3 h and 3, 6, 14, 21, and 35 days after i.v. inoculation,
respectively. 1, positive controls (whole blood spiked with C. albicans cells); 2,
negative controls (whole blood of uninfected control mice).
FIG. 4. Southern blot analysis of 10 ml of C. albicans PCR products obtained
from blood samples of mice treated with 1 (top) and 7 (bottom) mg of AmB per
kg. Lanes 1 to 3, 4 to 6, 7 to 9, 10 to 12, 13 to 16, and 17 to 19 represent mice
sacrificed at 3 h and 3, 6, 14, 21, and 35 days after i.v. inoculation, respectively.
1, positive controls (whole blood spiked with C. albicans cells); 2, negative
controls (whole blood of uninfected control mice).
TABLE 1. Blood culture and PCR hybridization results for neutropenic mice after i.v. inoculation with C. albicans
Time
Result with AmB regimena:
1 mg/kg 7 mg/kg 14 mg/kg
No. of
CFUb PCR
5c PCR10d No. ofCFU PCR
5 PCR10 No. ofCFU PCR
5 PCR10
1 h 0, 6, 4 1, 1, 1 1, 1, 1 1, 1, 7 2, 1, 1 1, 1, 1 8, 6, 6 1, 1, 1 2, 2, 2
3 days 0, 93, 0 2, 1, 2 1, 1, 1 0, 0, 0 2, 2, 2 2, 2, 2 0, 0, 0 2, 2, 2 2, 2, 2
6 days 0, 0, 0 2, 1, 1 1, 1, 1 0, 0, 0 2, 1, 2 1, 1, 1 0, 0, 0 2, 2, 2 2, 2, 2
14 days 0, 0, 0 2, 2, 2 1, 1, 1 0, 0, 0 1, 2, 2 1, 1, 2 0, 0, 0 1, 1, 2 2, 2, 2
21 days 0, 0, 0, 0 2, 1, 1, 1 1, 2, 2, 1 0, 0, 0, 0 1, 1, 2, 2 1, 1, 1, 1 0, 0, 0 1, 1, 1 2, 2, 2
35 days 0, 0, 0 1, 1, 1 1, 1, 1 0, 0, 0 1, 1, 2 1, 1, 2 0, 0, 0 2, 2, 2 2, 2, 2
aMice were treated with 1, 7, or 14 mg of AmB per kg for 4 days and sacrificed at the indicated intervals; data are from individual animals in each of three separate
experiments.
b Data are per 100 ml of blood.
c PCR5, hybridization signals obtained by using 5 ml of processed blood for PCR. 1, positive signal; 2, negative signal.
d PCR10, hybridization signals obtained by using 10 ml of processed blood for PCR. 1, positive signal; 2, negative signal.
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Berenguer et al. (1) demonstrated in a clinical setting the
existence of a correlation between the number of organs in-
fected by Candida spp. and the number of positive blood cul-
tures. Our results showed that blood cultures of infected mice
treated with three different doses of AmB were positive only at
the beginning of the treatment and became sterile within 3
days, even for mice treated with 1 mg of AmB per kg that
experienced a relapse of infection after 14 days. On the other
hand, a significant correlation between positive kidney cultures
and the PCR results was demonstrated. Likewise, hybridiza-
tion signals of the PCR increased with increasing numbers of
C. albicans CFU in the kidneys of untreated mice (14). This
correlation between positive kidney cultures and positivity of
the PCR can only be explained by the fact that intact Candida
cells are still present and detectable by PCR in the peripheral
circulation. Since in the DNA extraction procedure a DNase
treatment step is incorporated before the actual lysis of the
Candida cells, the possibility that we are detecting circulating
C. albicansDNA only is ruled out. Blood culture results for the
same samples were negative, however, probably because of the
low level or complete absence of metabolic activity of the
Candida cells or the inhibitory presence of residual AmB.
Strong hybridization signals were observed at day 35 with
mice that had been treated with a regimen of 7 mg of AmB per
kg for 4 days, suggesting a relapse of the infection despite
negative cultures from the kidneys, livers, lungs, and spleens at
that moment. This hypothesis could not be further analyzed
since we did not evaluate the progression of infection beyond
day 35. Samples obtained with regimen of 14 mg of AmB per
kg showed negative PCR results at day 35. This regimen might
thus be more effective than 7 mg of AmB per kg, implicating
that the mice treated with 7 mg of AmB per kg had not
completely cleared the Candida cells. On the other hand, false-
positive signals are not a problem with this PCR since multiple
blood samples from gastrointestinally colonized mice (14) and
normal control mice were all negative by PCR.
PCR with 5 ml of processed target DNA was less sensitive
than PCR with 10 ml of target DNA of blood samples in the in
vivo experiment for mice treated with 1 or 7 mg of AmB per kg,
indicating that more target DNA increases the sensitivity of the
PCR assay. Application of 15 ml of processed target DNA in
the PCR, however, caused false-negative results, probably due
to inhibitory factors present in the blood samples. For the same
reason, no hybridization signals were obtained by using 10 ml
of target DNA of blood samples of mice treated with 14 mg of
AmB per kg, whereas the same samples were PCR positive if
5 ml was used. This indicates the narrow window between
negative results due to inhibitory factors and the detection
limit of the assay. Therefore, to exclude false-negative PCR
results it may be necessary to routinely use several concentra-
tions of target DNA in the PCR assay. This limitation in
sensitivity of the PCR might be overcome in the near future if
rRNA instead of DNA is used, since there is a high copy
number of rRNA present in each cell. Another advantage of
rRNA is that it can be amplified in a commercially available
nucleic acid sequence-based amplification system, which is
faster than PCR (13) and whose enzymes are less sensitive to
inhibitory factors. The advantage of commercial systems is that
they are easy to perform and detection formats are less labo-
rious, which makes the introduction of these techniques into all
microbiology laboratories possible.
We conclude that in this neutropenic murine model of in-
vasive candidiasis, PCR results correlated well with the re-
sponse to the therapy administered. PCR is much better in this
respect than routine blood cultures. However, before this assay
can be used as a universal monitoring tool, PCR needs to be
further evaluated in this or other animal models and in a
clinical setting as well.
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